Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : LastShadow's Position Trading -- Ignore unavailable to you. Want to Upgrade?

To: tech fool who wrote (12432)	4/9/1999 4:57:00 PM
From: Judy	Read Replies (2) \| Respond to of 43080

I see more of a parallel between the internets and the networking stocks. Recall the early 90's when CSCO and WFLT were high-fliers played by momentum traders. Then FORE, ASND, COMS, USRX, CS, SHVA, CIEN, XYLN appeared on the horizon and flew high also. They all presented excellent investing potential and rich trading opportunities for a few years, no reason not to take advantage of that for it was not clear which would thrive and which would not. Tech investors must always keep alert to the changing horizon for today most of them are history ... CSCO remains strong, ASND becomes LU, and WFLT got absorbed by NT. But plenty of profits was had over the years. CSCO, one of my long-time core holdings, was just a trade for me back then, never heard of the stock before. I traded CMGI last year, never heard of the stock before, now it is an investment. First time I traded EXDS this March, never heard of the stock before. In fact, Tech Fool, you posted a link to an article about the stock and I examined the stock and entered ... so it goes.

To: tech fool who wrote (12432)	4/10/1999 1:34:00 PM
From: Jeff Sutton	Respond to of 43080

I see parallels between nets and biotechs only in the public buying frenzy. Otherwise, the analogy breaks down. The differences: (1) People can see the net's dramatic effects in their daily lives, usually not so with biotechs (unless, of course, a new drug offers salvation to you or someone you know with a life-threatening illness) (2) Biotechs are totally dependent on results of phase II and III trials, FDA approval, etc. A failed trial can decimate a biotech in a flash. Again, nets are different. By the way, we may just be entering another phase of biotech frenzy what with the new cancer developments. Look at what happened to ENMD's stock a few months back. Not a bad idea to keep a couple of speculative biotechs in your portfolio. Some day (I hope), cancer and AIDS and other diseases will be cured. The biotechs who develop drugs to rid mankind of these scourges will, obviously, soar. But who knows when this will be or what companies will succeed?